This great company’s cheap shares have crashed 25% in 10 months. I’d buy today!

After a sizeable surge since Halloween, the FTSE 100 index is taking a breather. As I write, the index is down roughly 125 points (1.9%) from Monday’s mid-afternoon peak of 6,455. Nevertheless, the Footsie has gained almost 745 points (13.3%) since October, making this a positive month for UK shareholders. […]

After a sizeable surge since Halloween, the FTSE 100 index is taking a breather. As I write, the index is down roughly 125 points (1.9%) from Monday’s mid-afternoon peak of 6,455. Nevertheless, the Footsie has gained almost 745 points (13.3%) since October, making this a positive month for UK shareholders. On the other side of the Atlantic, news of a highly effective Covid-19 vaccine from US biotech Moderna lifted stock prices again. Yesterday, the S&P 500 index closed at a record closing high of 3,627 points, up 11.2% in 2020. Despite these recent rises, I still see hidden value in quality FTSE 100 companies selling cheaply today. For example, I’d buy these cheap shares right now.

GSK is one of my favourite FTSE 100 stocks

Habitual Fool readers will know that I write about GlaxoSmithKline (LSE: GSK) more often than almost any other FTSE 100 firm. That’s because I regard its cheap shares of one of the biggest low-risk bargains in the entire Footsie. Having been a GSK shareholder for most of the past 30 years, I’ve followed its fortunes over the decades. Also, I’ve had a couple of close relatives work in leading scientific roles at GSK, so I’ve seen the company from the inside.

Under new CEO (and recent Dame) Emma Walmsley, GSK has been undergoing enforced evolution. It is now focused on being a world leader in immunology, oncology (cancer), HIV/AIDS, respiratory treatments, and vaccines. And, being the UK’s second-largest pharmaceutical company, you’d expect the Covid-19 pandemic to boost GSK’s share price, right? Wrong, because these cheap shares just keep getting cheaper.

Cheap shares: GSK is down 25% in 10 months

As I write, the GSK share price is 1,395p, having falling back 47p (3.3%) overnight. Although this is 111p (8.6%) above the stock’s 52-week closing low of 1,284p on 30 October, I believe GSK’s cheap shares have far further to rise. After all, at their 2020 high on 24 January, they closed at 1,857p, which is 1.33 times the current price. In other words, GSK shares have fallen almost exactly a quarter (24.9%) in 10 months, which puts them in crash territory.

In my view, GSK’s cheap shares should appeal to a wide range of conservative investors, such as value seekers and income investors. GSK is what I call an ‘SLR share’, in that it offers Safety, Liquidity, and Returns, as follows:

  • Safety: GSK is a FTSE 100 heavyweight with a market value of £73.4bn, so you know it’s not going to go away any time soon.
  • Liquidity: GSK shares are among the most liquid, being easy to buy and sell in very large quantities.
  • Returns: For the past five years, GSK shares have paid a yearly dividend of 80p.

Today, GSK’s cheap shares offer a chunky dividend yield of 5.73%. This is about 1.8 times the FTSE 100’s dividend yield of roughly 3.2%. In fact, at £4bn a year, GSK’s yearly cash payout is the fifth-largest by size in the entire UK stock market. Also, GSK’s stock is cheap in historical valuation terms. It trades on a price-to-earnings ratio of around 10.8 and an earnings yield of 9.3%.

For me and other GSK shareholders, 2020 hasn’t been a great year. But I think 2021 will see GSK producing much higher returns, especially for investors buying in at these depressed prices. That’s why I’d buy these cheap shares today, ideally inside an ISA, to pocket decades of tax-free cash dividends and future capital gains!

A Top Share with Enormous Growth Potential

Savvy investors like you won’t want to miss out on this timely opportunity…

Here’s your chance to discover exactly what has got our Motley Fool UK analyst all fired up about this ‘pure-play’ online business (yes, despite the pandemic!).

Not only does this company enjoy a dominant market-leading position…

But its capital-light, highly scalable business model has previously helped it deliver consistently high sales, astounding near-70% margins, and rising shareholder returns … in fact, in 2019 it returned a whopping £150m+ to shareholders in dividends and buybacks!

And here’s the really exciting part…

While COVID-19 may have thrown the company a curveball, management have acted swiftly to ensure this business is as well placed as it can be to ride out the current period of uncertainty… in fact, our analyst believes it should come roaring back to life, just as soon as normal economic activity resumes.

That’s why we think now could be the perfect time for you to start building your own stake in this exceptional business – especially given the shares look to be trading on a fairly undemanding valuation for the year to March 2021.

Click here to claim your copy of this special report now — and we’ll tell you the name of this Top Growth Share… free of charge!

More reading

Cliffdarcy owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

The post This great company’s cheap shares have crashed 25% in 10 months. I’d buy today! appeared first on The Motley Fool UK.

ASNF

Next Post

How Nonprofits Can Leverage the Latest Trend in For-Profit Technology

Wed Nov 18 , 2020
For-profit brands have been buzzing about the latest technology to have a big impact on the market: customer data platforms (CDP). Salesforce recently launched its own: Customer 360 Audiences. A CDP is software that can do a few things, like:  Connect customer data in a single place Reconcile customer identities […]